Replies to post #218428 on Biotech Values

[mcbio]

ALXN acquires WTX.ST for SEK 232/sh—a 70% premium to yesterday’s close

I had kicked the tires on WTX.ST before but ultimately chose to pass, in part, due to a competitive threat from private French gene therapy player Vivet Therapeutics: https://www.vivet-therapeutics.com/en . They have a gene therapy for Wilson's disease that is set to enter the clinic 4Q this year with PoC data expected around the time of the pivotal P3 data for WTX.ST's drug (WTX101) in 2H19. Evidently, ALXN doesn't view Vivet's gene therapy as a serious threat.